Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575666 · ClinicalTrials.gov registry record · Phase 4
Intranasal Insulin Treatment in Patients With Schizophrenia
A Phase 4 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT00575666 is a Phase 4 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 45 participants.
The verdict
NCT00575666, a Phase 4 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on psychopathology and cognition. In addition, the study will examine insulin's effects on weight, food intake, resting energy expenditure, and body composition.
Interventions
- DRUG Insulin or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575666
The ClinicalTrials.gov registry entry for NCT00575666 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Insulin or Placebo is the first listed.
NCT00575666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575666 about?
NCT00575666 is a clinical study titled "Intranasal Insulin Treatment in Patients With Schizophrenia". This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on psychopathology and cognition. In addition, the study will examine insulin's e...
What is the current status of trial NCT00575666?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2007-12. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00575666?
The interventions under investigation include: Insulin or Placebo (DRUG).
Who is sponsoring clinical trial NCT00575666?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.